An accountant as president, and the move to a holding company (2010)

Under whose discipline should a technical monopoly be run?

At the heart of this decision is a company that had reached the top on technology choosing to locate its next source of value not in the laboratory but in capital allocation and group management. Placing at its apex an accountant — neither an engineer nor a member of the founding family — while readying the vessel of a holding company at the same time, was a design meant to shift the weight of management toward finance and M&A once development had run its course. In deliberately swapping out the very character of who would run the company after a single success had taken hold, one senses a distinctive boldness.

That design, however, would summon a different question fifteen years on. The diversification President Sato pursued — the investment in pharmaceuticals above all — was challenged by some shareholders on the ground of capital efficiency, and in 2025 it reached the point where his reappointment as a director was voted down at the general meeting. The company is moving toward accepting a proposal to go private. How the finance-led management structure installed across 2010 and 2011 came, in time, to be the thing its own shareholders put under scrutiny is a subject for a separate account. The question of under whose discipline a world-leading technology should be put to work remains open.